iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
| Weiss Ratings | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.64 | |||
| Price History | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.96% | |||
| 30-Day Total Return | -4.01% | |||
| 60-Day Total Return | -9.50% | |||
| 90-Day Total Return | -16.30% | |||
| Year to Date Total Return | -8.99% | |||
| 1-Year Total Return | -36.76% | |||
| 2-Year Total Return | -55.20% | |||
| 3-Year Total Return | -80.03% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -59.89% | |||
| 52-Week Low % Change | 12.74% | |||
| Price | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.75 | |||
| 52-Week Low Price | $6.67 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | May 10, 2024 | |||
| Valuation | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 287.22M | |||
| Enterprise Value | -202.33M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.31 | |||
| Earnings Per Share Growth | 5.08% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 9.28 | |||
| Price/Book (Q) | 0.47 | |||
| Enterprise Value/Revenue (TTM) | -5.78 | |||
| Price | $7.19 | |||
| Enterprise Value/EBITDA (TTM) | 1.30 | |||
| Enterprise Value/EBIT | 1.29 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.18M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 339 217 0161 | |||
| Address | 321 Arsenal Street Watertown, MA 02472 | |||
| Website | www.iteostherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -448.02% | |||
| Profit Margin | -384.04% | |||
| Management Effectiveness | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.47% | |||
| Return on Equity | -- | |||
| Income Statement | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 35.00M | |||
| Total Revenue (TTM) | 35.00M | |||
| Revenue Per Share | $0.81 | |||
| Gross Profit (TTM) | 35.00M | |||
| EBITDA (TTM) | -155.57M | |||
| EBIT (TTM) | -156.81M | |||
| Net Income (TTM) | -134.41M | |||
| Net Income Avl. to Common (TTM) | -134.41M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -43.08% | |||
| EPS Diluted (TTM) | -3.31 | |||
| EPS Diluted Growth (Q YOY) | -18.70% | |||
| Balance Sheet | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 494.65M | |||
| Cash Per Share (Q) | $11.46 | |||
| Total Current Assets (Q) | 509.54M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 590.29M | |||
| Current Ratio (Q) | 12.625 | |||
| Book Value Per Share (Q) | $16.14 | |||
| Total Assets (Q) | 686.98M | |||
| Total Current Liabilities (Q) | 40.36M | |||
| Total Debt (Q) | 5.10M | |||
| Total Liabilities (Q) | 96.68M | |||
| Total Common Equity (Q) | 590.29M | |||
| Cash Flow | ITOS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -131.15M | |||
| Cash from Financing (TTM) | 122.24M | |||
| Net Change in Cash (TTM) | -109.02M | |||
| Levered Free Cash Flow (TTM) | -64.35M | |||
| Cash from Operations (TTM) | -98.18M | |||
